JP2017534577A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534577A5 JP2017534577A5 JP2017514474A JP2017514474A JP2017534577A5 JP 2017534577 A5 JP2017534577 A5 JP 2017534577A5 JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017534577 A5 JP2017534577 A5 JP 2017534577A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- antibody
- cdr
- pdl1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050745P | 2014-09-15 | 2014-09-15 | |
| US62/050,745 | 2014-09-15 | ||
| PCT/US2015/050051 WO2016044189A1 (en) | 2014-09-15 | 2015-09-14 | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020143036A Division JP2021001176A (ja) | 2014-09-15 | 2020-08-26 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017534577A JP2017534577A (ja) | 2017-11-24 |
| JP2017534577A5 true JP2017534577A5 (OSRAM) | 2018-10-25 |
Family
ID=54325043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514474A Withdrawn JP2017534577A (ja) | 2014-09-15 | 2015-09-14 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
| JP2020143036A Pending JP2021001176A (ja) | 2014-09-15 | 2020-08-26 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020143036A Pending JP2021001176A (ja) | 2014-09-15 | 2020-08-26 | Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20170274073A1 (OSRAM) |
| EP (1) | EP3194440A1 (OSRAM) |
| JP (2) | JP2017534577A (OSRAM) |
| CN (1) | CN106687135A (OSRAM) |
| WO (1) | WO2016044189A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| CN108884139A (zh) | 2015-11-02 | 2018-11-23 | 戊瑞治疗有限公司 | Cd80胞外域多肽及其在癌症治疗中的用途 |
| US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
| WO2017136497A1 (en) * | 2016-02-03 | 2017-08-10 | The Cleveland Clinic Foundation | Detection and treatment of il-17 and il-13 related conditions |
| WO2017174759A1 (en) * | 2016-04-08 | 2017-10-12 | Centre National De La Recherche Scientifique | Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment |
| WO2018027524A1 (en) * | 2016-08-09 | 2018-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibody formulation |
| EP3528834A4 (en) * | 2016-10-21 | 2020-07-01 | Merck Sharp&Dohme Corp. | TREATMENT OF CANCER USING A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 ANTAGONIST |
| EA201992586A1 (ru) | 2017-04-28 | 2020-03-03 | Файв Прайм Терапьютикс, Инк. | Способы лечения с помощью полипептидов внеклеточного домена cd80 |
| WO2018217976A1 (en) * | 2017-05-25 | 2018-11-29 | Bristol-Myers Squibb Company | Antagonistic cd40 monoclonal antibodies and uses thereof |
| EP3641813A4 (en) | 2017-06-18 | 2021-04-21 | Kindred Biosciences, Inc. | IL17A ANTIBODIES AND ANTAGONISTS FOR USE IN VETERINARY MEDICINE |
| CA3071337A1 (en) | 2017-08-15 | 2019-02-21 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
| EP3483180A1 (en) * | 2017-11-14 | 2019-05-15 | Affilogic | Multi specific molecules |
| CA3084370A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| US12109249B2 (en) | 2018-01-30 | 2024-10-08 | University Of Louisville Research Foundation | Compositions and methods for treating inflammation and cancer |
| CA3100200A1 (en) * | 2018-05-21 | 2019-11-28 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| CN110563842B (zh) * | 2018-06-06 | 2022-07-29 | 浙江博锐生物制药有限公司 | 针对程序性死亡配体(pd-l1)的抗体及其应用 |
| KR102091637B1 (ko) * | 2018-07-10 | 2020-03-20 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN109053891B (zh) * | 2018-09-17 | 2021-12-21 | 苏州泓迅生物科技股份有限公司 | 一种抗pd-l1抗体及其制备方法和应用 |
| WO2020150208A1 (en) * | 2019-01-14 | 2020-07-23 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors |
| WO2020201442A1 (en) * | 2019-04-03 | 2020-10-08 | Orega Biotech | Combination therapies based on pd1 and il-17b inhibitors |
| WO2020218322A1 (ja) * | 2019-04-23 | 2020-10-29 | 国立大学法人東北大学 | 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測 |
| CN115698717A (zh) * | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| JP2023525234A (ja) * | 2020-04-30 | 2023-06-15 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｉｌ－１７経路のモジュレータを同定する方法 |
| US20240400668A1 (en) * | 2022-07-29 | 2024-12-05 | Jinfeng Laboratory | Non-human mammalian model expressing il-8 and use thereof |
| WO2025003035A1 (en) * | 2023-06-30 | 2025-01-02 | Universitätsklinikum Essen | Il-17 based therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
| TR201820873T4 (tr) * | 2011-08-01 | 2019-01-21 | Hoffmann La Roche | Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler. |
| BR112014003599A2 (pt) * | 2011-08-17 | 2018-04-17 | Genentech Inc | método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor |
| KR101463325B1 (ko) * | 2013-01-14 | 2014-11-20 | 가톨릭대학교 산학협력단 | HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물 |
-
2015
- 2015-09-14 JP JP2017514474A patent/JP2017534577A/ja not_active Withdrawn
- 2015-09-14 WO PCT/US2015/050051 patent/WO2016044189A1/en not_active Ceased
- 2015-09-14 EP EP15780971.6A patent/EP3194440A1/en not_active Withdrawn
- 2015-09-14 CN CN201580048941.5A patent/CN106687135A/zh active Pending
-
2017
- 2017-03-02 US US15/448,437 patent/US20170274073A1/en not_active Abandoned
-
2019
- 2019-06-26 US US16/453,650 patent/US20200155676A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,805 patent/US20200405855A1/en not_active Abandoned
- 2020-08-26 JP JP2020143036A patent/JP2021001176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017534577A5 (OSRAM) | ||
| JP2017501167A5 (OSRAM) | ||
| FI4141032T3 (fi) | T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito | |
| JP2023123726A5 (OSRAM) | ||
| JP2020500538A5 (OSRAM) | ||
| JP2016510002A5 (OSRAM) | ||
| JP2017514461A5 (OSRAM) | ||
| JP2018035138A5 (OSRAM) | ||
| JP2015509947A5 (OSRAM) | ||
| JP2016505546A5 (OSRAM) | ||
| JP2018521638A5 (OSRAM) | ||
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| JP2017507900A5 (OSRAM) | ||
| JP2018108081A5 (OSRAM) | ||
| JP2017113028A5 (OSRAM) | ||
| JP2017501157A5 (OSRAM) | ||
| JP2014158469A5 (OSRAM) | ||
| JP2018508483A5 (OSRAM) | ||
| JP2013198490A5 (OSRAM) | ||
| JP2017528476A5 (OSRAM) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| JP2018505177A5 (OSRAM) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| JP2014511179A5 (OSRAM) | ||
| JP2018507220A5 (OSRAM) |